| AKT2 and XIST expression was identified as a potential biomarker participating in the effect of ATP5J in colorectal cancer | Identification of candidate genes and long non-coding RNAs associated with the effect of ATP5J in colorectal cancer.
Bai B, Xie B, Pan Z, Shan L, Zhao J, Zhu H., Free PMC Article | 08/25/2018 |
| CF6-induced increase in apoptotic cells was blocked by immature or mature IF1, being accompanied by protein kinase B (PKB) phosphorylation. IF1 antagonizes the pro-apoptotic action of CF6 by relief of intracellular acidification and resultant phosphorylation of PKB. | Mitochondrial Inhibitory Factor Protein 1 Functions as an Endogenous Inhibitor for Coupling Factor 6.
Kawai M, Osanai T, Tanaka M, Magota K, Tomita H, Okumura K. | 09/16/2017 |
| Over-expression of the ATP5J gene correlates with cell migration and 5-fluorouracil sensitivity in colorectal cancer. | Over-expression of the ATP5J gene correlates with cell migration and 5-fluorouracil sensitivity in colorectal cancer.
Zhu H, Chen L, Zhou W, Huang Z, Hu J, Dai S, Wang X, Huang X, He C., Free PMC Article | 05/24/2014 |
| CF6 plays a crucial role in the development of insulin resistance and hypertension | Coupling factor 6-induced activation of ecto-F1F(o) complex induces insulin resistance, mild glucose intolerance and elevated blood pressure in mice.
Osanai T, Tanaka M, Magota K, Tomita H, Okumura K. | 06/23/2012 |
| The phenotypic range of retinal, peripheral and central nervous system disease expression is characterized in a single family with NARP syndrome from the ATPase 6 m.8993T>C mtDNA point mutation. | Heterogeneous patterns of tissue injury in NARP syndrome.
Gelfand JM, Duncan JL, Racine CA, Gillum LA, Chin CT, Zhang Y, Zhang Q, Wong LJ, Roorda A, Green AJ., Free PMC Article | 01/14/2012 |
| coupling factor 6 induces the development of systolic dysfunction and upregulation of nicotinamide adenine dinucleotide phosphate oxidase in the heart under the high-salt diet | Overexpression of coupling factor 6 causes cardiac dysfunction under high-salt diet in mice.
Ashitate T, Osanai T, Tanaka M, Magota K, Echizen T, Izumiyama K, Yokoyama H, Shibutani S, Hanada K, Tomita H, Okumura K. | 02/5/2011 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (2) articlesGenetic variants in nuclear-encoded mitochondrial genes influence AIDS progression.
Hendrickson SL, Lautenberger JA, Chinn LW, Malasky M, Sezgin E, Kingsley LA, Goedert JJ, Kirk GD, Gomperts ED, Buchbinder SP, Troyer JL, O'Brien SJ. Polymorphisms in mitochondrial genes and prostate cancer risk.
Wang L, McDonnell SK, Hebbring SJ, Cunningham JM, St Sauver J, Cerhan JR, Isaya G, Schaid DJ, Thibodeau SN. | 09/20/2009 |
| Coupling factor 6 enhances Src-mediated responsiveness to angiotensin II in resistance arterioles and cells. | Coupling factor 6 enhances Src-mediated responsiveness to angiotensin II in resistance arterioles and cells.
Osanai T, Tomita H, Kushibiki M, Yamada M, Tanaka M, Ashitate T, Echizen T, Katoh C, Magota K, Okumura K. | 01/21/2010 |
| T8993G allele causes severe extrapyramidal dysfunction and Leigh disease but there is no correlation between the degree of enzyme deficiency and the severity of the phenotype. | Clinical and biochemical characteristics in patients with a high mutant load of the mitochondrial T8993G/C mutations.
Morava E, Rodenburg RJ, Hol F, de Vries M, Janssen A, van den Heuvel L, Nijtmans L, Smeitink J. | 01/21/2010 |
| in vascular endothelial cells both CF6 (coupling factor 6) and Angiotensin II downregulate PECAM-1 (platelet/endothelial cell adhesion molecule) expression via activation of c-Src kinase | Coupling factor 6 downregulates platelet endothelial cell adhesion molecule-1 via c-Src activation and acts as a proatherogenic molecule.
Kumagai A, Osanai T, Katoh C, Tanaka M, Tomita H, Morimoto T, Murakami R, Magota K, Okumura K. | 01/21/2010 |
| Mutation analysis revealed the T9176C mutation in the mtATPase 6 gene (OMIM 516060) and the mutation load was above 90% in the patients with Leigh syndrome. | Transmission and prenatal diagnosis of the T9176C mitochondrial DNA mutation.
Jacobs LJ, de Coo IF, Nijland JG, Galjaard RJ, Los FJ, Schoonderwoerd K, Niermeijer MF, Geraedts JP, Scholte HR, Smeets HJ. | 01/21/2010 |
| CF6 is a novel risk factor for ischemic heart disease in end-stage renal disease. Synergism of this peptide and asymmetric dimethylarginine might contribute to its occurrence presumably by inhibition of prostacyclin and nitric oxide production. | Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease.
Osanai T, Nakamura M, Sasaki S, Tomita H, Saitoh M, Osawa H, Yamabe H, Murakami S, Magota K, Okumura K. | 01/21/2010 |
| Plasma CF6 elevated in patients with acute myocardial infarction. At 3 days, plasma CF6 correlated positively with plasma creatinine kinase peak value and correlated negatively with left ventricular ejection fraction. | Plasma mitochondrial coupling factor 6 in patients with acute myocardial infarction.
Ding WH, Chu SY, Jiang HF, Cai DY, Pang YZ, Tang CS, Qi YF. | 01/21/2010 |
| Membrane-bound ATP synthase functions as a receptor for CF6 and may have a previously unsuspected role in the genesis of hypertension by modulating the concentration of intracellular hydrogen. | Intracellular signaling for vasoconstrictor coupling factor 6: novel function of beta-subunit of ATP synthase as receptor.
Osanai T, Magota K, Tanaka M, Shimada M, Murakami R, Sasaki S, Tomita H, Maeda N, Okumura K. | 01/21/2010 |
| Increased CF6 may be responsible in part for decreased prostacyclin observed in coronary heart disease, in particular after PTCA and stent therapy. Potential risk factor for coronary heart disease. | Plasma level of mitochondrial coupling factor 6 increases in patients with coronary heart disease.
Chai SB, Hui YM, Li XM, Tang CS. | 01/21/2010 |